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ABSTRACT
Synthetic biology is interpreted as the engineering-driven building
of increasingly complex biological entities for novel applications.
Encouraged by progress in the design of artificial gene networks, de
novo DNA synthesis and protein engineering, we review the case for
this emerging discipline. Key aspects of an engineering approach
are purpose-orientation, deep insight into the underlying scientific
principles, a hierarchy of abstraction including suitable interfaces
between and within the levels of the hierarchy, standardization and
the separation of design and fabrication. Synthetic biology investigates
possibilities to implement these requirements into the process of
engineering biological systems. This is illustrated on the DNA level
by the implementation of engineering-inspired artificial operations
such as toggle switching, oscillating or production of spatial patterns.
On the protein level, the functionally self-contained domain structure
of a number of proteins suggests possibilities for essentially Lego-
like recombination which can be exploited for reprogramming DNA
binding domain specificities or signaling pathways. Alternatively,
computational design emerges to rationally reprogram enzyme
function. Finally, the increasing facility of de novo DNA synthesis—
synthetic biology’s system fabrication process—supplies the possibility
to implement novel designs for ever more complex systems. Some of
these elements have merged to realize the first tangible synthetic
biology applications in the area of manufacturing of pharmaceutical
compounds.
Contact: panke@ipe.mavt.ethz.ch
1 INTRODUCTION
The advent of systems biology, the steady development of foun-
dational technologies such as de novo DNA synthesis (Tian et al.,
2004), milestone experiments such as the computational re-design
of enzymes (Dwyer et al., 2004), the opportunity to widely recom-
bine zinc fingers to re-program DNA-binding site specificity
(Dreier, 2001) and the availability of well-studied model regulat-
ory systems for the design of engineering-inspired molecular
devices provide a very powerful knowledge and technology basis
for building novel biological entities. Encouraging applications
come from such diverse areas as the design of artificial gene
networks (Sprinzak and Elowitz, 2005), the refactoring of small
genomes (Chan et al., 2005), the reprogramming of signaling
pathways (Dueber et al., 2003) or metabolic engineering (Martin
et al., 2003) and have been referred to as ‘synthetic biology’. These
applications entertain the notion that adaptation and assembly of
functionally self-contained parts such as promoters, ribosome
binding sites, coding sequences, terminators or protein domains
are a promising way to re-constitute existing or to produce
novel, biological entities. To extend such an approach to the
many opportunities typically associated with the application of
biological systems, we need to establish a number of rules. Building
novel parts, devices and in particular complex systems will
require a systematic approach that relies on modularity and abst-
raction at various cellular levels in order to be useful to a broad
group of biotechnologists. It will also require a technology to
fabricate the designs, more precisely, the DNA encoding the
system. This is synonymous to following an engineering approach,
even if biology is in many aspects not understood well enough
to consider it a sufficient knowledge base for an engineering
discipline
This review will discuss prominent works that have helped
launching this engineering vision and it will attempt–in one review–
to touch upon all the fields that we perceive as the currently most
relevant to synthetic biology, spanning the entire trajectory from
design via fabrication to applications on protein, gene network and
systems level. Several separate aspects of these fields have recently
been reviewed. (Andrianantoandro et al., 2006; Benner and
Sismour, 2005; Endy, 2005; Forster and Church, 2006; Hasty
et al., 2002; Kærn et al., 2003; McDaniel and Weiss, 2005;
Sprinzak and Elowitz, 2005). However, we reason that it is impor-
tant to cover all major aspects of the engineering vision in one
review to give emphasis to synthetic biology’s rather comprehen-
sive claim of re-organizing the bioengineering endeavor. After a
brief discussion on the fundamental characteristics of an engineer-
ing approach, we bring together prominent examples from these
aspects and finally discuss the requirements and implications for
bioinformatics.
2 TOWARDS ENGINEERING OF BIOLOGY
Engineers’ efforts in the field of engineering biology are furnished
with only a few success stories. This reflects the fact that the ability
to engineer biology in a directed and successful manner is still rather
limited today and as a consequence, the complexity of things we can
efficiently make is still quite small. Synthetic biology with its engi-
neering vision aims to overcome the existing fundamental inabili-
ties in system design and system fabrication, by developing
foundational principles and technologies to ultimately enable a
systematic forward-engineering of (parts of) biological systems
for improved and novel applications (Fig. 1). Conceptually, this
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needs to encompass several characteristic features of other
established engineering disciplines (Endy, 2005):
(1) In non-biology related areas, engineers can usually draw on a
sound knowledge base. In-depth understanding (sometimes
down to the first principles) permits computer-based design
of new systems by going through iterations between computer
models and simulations. This allows an extensive in silico
testing of new design variants.
(2) The application of abstraction hierarchies is a common char-
acteristic in almost every engineering endeavor and results in
several practical advantages. First, the introduction of system
boundaries basically hides information and is thus a way to
manage complexity. In other words, abstraction is useful as it
allows individuals to work independently at each level of the
hierarchy. It is an organizational prerequisite for combining
parts into complex systems.
(3) In order to guarantee ‘plug-and-play’ compatibility of differ-
ent components in an abstraction hierarchy, the connections
between the different parts need to be defined, i.e. standardiza-
tion is required. Only broadly implemented standards for the
components themselves and their in- and output criteria would
ensure that interfaces between components fit, evenwhen they
are designed and fabricated by different laboratories or,
ultimately, different companies.
(4) Finally, another characteristic feature of ‘true’ engineering is
the decoupling of the design process from the actual fabrica-
tion of components or systems. Both tasks require a distinct set
of skills and expertise, which is typically not provided by the
same individuals. However, as a consequence this separation
requires that the design engineers also need to have a sound
knowledge about how things are actually produced and how
parts are assembled. In other words, the design for an object is
useless if it has been designed in such a way that no possibility
exists to fabricate it.
We argue that design in biology along these engineering char-
acteristics is a realistic goal, to a sufficiently promising extent, for
the following reasons:
(1) There is a ubiquitous tendency to move from qualitative to
quantitative analyses in biological sciences. This starts to
provide on a large scale the data sets that are needed to under-
stand and structure biological complexity, e.g. by means of
mathematical models. Even if the complexity we can manage
does not currently go much beyond small artificial gene net-
works, whose DNA-basis can be designed relatively indepen-
dently from the remaining cellular environment, our ever
increasing knowledge and system understanding will allow
us to extend our realm of design further and further.
(2) The introduction of system boundaries in living systems is
of course difficult as information flow relies on the diffusion
of molecules through the cytoplasm. This entails all sorts of
cross-activities and complicates the design of functionally
self-contained elements. Furthermore, many cellular elements
havemore than one function. On the other hand, we are able to
engineer excellent specificities in small molecule–protein,
DNA–protein and protein–protein interactions that help to
functionally separate different elements. Furthermore, work
onorthogonal (i.e. insulated) translational systems ingeneral is
only about to start and first results are encouraging (Isaacs
et al., 2004;RackhamandChin, 2005).Finally, there are strong
ongoing efforts towardsminimal (bacterial) systems and it can
be expected that such systems–owing to their reduced
complexity–have a much smaller number of cross-reactions,
so that implementation of novel elements stands a much better
chance of remaining functionally isolated. In summary, we
reason that even though proper system boundaries might be
difficult to implement in current biological systems, there is
good indication that these systems can be sufficiently adapted
to allow this in the near future.
(3) The wide-spread implementation of standards in biological
design has never been a serious issue in biotechnology. This
fact resulted in a large diversity in bioengineering tools
(strains, plasmids, expression systems, etc) which hampers
the wide distribution of biological parts across laboratories.
Current attempts to implement standards (see below) have
the potential to fundamentally change this and have already
helped to enable the operation of large projects such as the
iGEM2006 competition (http://parts.mit.edu), where >30 pro-
jects all over the world rely on and provide parts for one parts
warehouse.
(4) Finally, the biological equivalent to fabrication is genomic
scale de novo DNA synthesis, which—as we will discuss
below—is increasingly possible already today.
We have to point out that there is a fundamental difference
between engineering biology and engineering in other natural sci-
ences such as chemistry or physics: biological systems have the
capacity to replicate and to evolve. This fundamental characteristic
will interfere at least with the long-term stability of a number of
designed systems and will require constant monitoring of the
integrity (of crucial parts) of the systems. As the ultimate goal
will be to build complex systems into specific hosts, it is likely
that interference from mutations becomes a serious issue. However,
it is important to point out that the problem as such is not new to
biotechnology—rather, it has accompanied every major strain
development effort in industrial fermentation and has contributed
to the development of appropriate selection programs for suffi-
ciently stable strains and suitable strain storage routines.
In summary, we see synthetic biology as a novel, true engineering
approach to conducting biotechnology. In synthetic biology, we
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Fig. 1. Synthetic Biology encompasses systems design and fabrication. Each
part has its specific prerequisites and inputs. Ultimately, synthetic biology
will deliver novel biological entities with improved functionality.
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would include endeavors that exploit at least some of the important
elements of an engineering approach, as discussed, in their
methodology. e.g. de novo DNA synthesizing an entire pathway,
which is composed of genes from various species and includes
optimized codon usage, adapted secondary mRNA structure, tai-
lored regulatory elements and a restriction site strategy that allows
the modular replacement of specific genes by improved versions,
can be considered a synthetic biology approach to a metabolic
engineering problem. Alternatively, the forward-engineering design
of genetic modules that can be freely combined to program gene
regulation can be considered a synthetic biology approach to genetic
engineering.
3 TOOLS AND ENABLING TECHNOLOGIES
FOR SYNTHETIC BIOLOGY—FABRICATION
Synthetic biology aims to follow the standard engineering
protocol of design and fabrication. We will discuss first, the status
of a number of items related to the issue of fabrication, including
standardized cloning, de novo DNA synthesis and work on
minimizing genomes.
3.1 Standardized cloning
Today, traditional cloning represents the most important fabrication
tool in synthetic biology. Using standard, typically PCR-based
technologies, an existing DNA fragment is adapted for a novel
purpose and inserted into one of a myriad of different cloning
vectors according to the specifications of the multi-cloning site.
Insertion of alternative elements from vectors with different restric-
tion site structures (e.g. from different laboratories), introduction of
point mutations for novel restriction sites or adaptation of codon
usage, etc. all require several rounds of manipulations. In other
words, the current system fabrication process is laborious and
inefficient.
An important initial step to improve the situation could be the
introduction of a standardized vector format which lends itself
easily to assemble and allows interoperability of the assembled
sequences, such as the set of ‘idempotent vectors’ (https://dspace.
mit.edu/bitstream/1721.1/21168/1/biobricks.pdf) or the NOMAD
technology (Rebatchouk et al., 1996). Here, vectors are designed
in such a way that insertion of a DNA fragment into a vector recre-
ates exactly the same restriction site architecture. This way, multiple
rounds of insertion on either side of an insert are easily possible.
Through the implementation of such standards, rapid exchange of
parts is made possible and in fact realized by the ‘Registry of
Standard Biological Parts’ of the Massachusetts Institute of Tech-
nology working group on synthetic biology (http://parts.mit.edu).
The registry intends to serve as a source of well characterized parts
that have been formatted according to specific rules, to make assem-
bly easy. Furthermore, the organization of the registry into basic
DNA parts such as promoters, ribosome binding sites (RBS) and
coding sequences sparks the hope that it will become much easier to
obtain suitable genetic elements for a specific design purpose, so
that ultimately desired experimental outcomes can be achieved
much faster.
Of course, the ideas for standardization need to remain open
for optimization and will hopefully include in the future standard-
ization of strains as well as vectors and directions on which suitable
cellular parameters should be quantified by which standardized
protocol. Here, it should be pointed out, that in many cases the
means to rapidly quantify the important connections and inter-
actions between parts hardly exist, not even for such a simple
concept as promoter strength. In other words, to be successful as
an engineering discipline, synthetic biology will need to repeat the
corresponding developments of its sister engineering disciplines
that have lead to highly organized fields such as mechanical and
electrical engineering.
3.2 De novo DNA synthesis
Even after the potential improvements in standardization and organ-
ization discussed above, parts and especially system assembly will
remain a major issue in any synthetic biology project. The question
of how to produce physical instances of systems requiring 10 (exist-
ing gene networks) or 100 kb (genome re-programming) of novel
DNA sequence is basically, still, unsolved. It will be imperative to
provide access to de novo synthesized DNA sequences. This tech-
nology will allow assembly of all the desired changes from pro-
moter strength to codon usage directly into a novel sequence. This
sequence should then be available within weeks or even days after
its design.
DNAdenovo synthesis is currently performedbyassemblingover-
lapping short (25–70 bp long) and chemically synthesized oligonu-
cleotides into longer DNA fragments in a PCR-based assembly
process (Stemmer et al., 1995). This technology has already led to
the complete reconstruction of some smaller phage genomes such as
thepolio virus (Cello et al., 2002).However, it suffers from twomajor
cost entries: the costs of synthesizing the DNA oligonucleotides by
standard phosphoamidite chemistry and the limitations in the accu-
racyof thechemical synthesis (YoungandDong, 2004).For example,
the de novo reconstruction of the phage FX174 genome relied on a
2-foldselectionprocess: (1)oligonucleotideswerefirstgel-purified to
ensure the correct length of the set and (2) correctly assembled DNA
was recovered from plaques after transformation, effectively provid-
ing a positive selection strategy for biological function (Smith et al.,
2003). Cost and accuracy associated with the current synthesis
method will have to be addressed before de novo DNA synthesis
can become the routine technology that will be required to fabricate
more complex biological systems.
Research to optimize the current procedure follows three paths:
(1) miniaturizing oligonucleotide production; (2) optimizing
sequence verification costs; and (3) eliminating ‘false’ oligonu-
cleotides by enzymatic and/or hybridization methods.
(1) Regarding miniaturization, a promising, though not yet fully
developed, option is the utilization of microfluidics-based
arrays for synthesis. Exploiting the small scale should lead
not only to a reduction in the materials costs but also allow
optimized reaction conditions and thus reduce error freq-
uencies (Zhou et al., 2004). Alternatively, oligonucleotide
synthesis has been miniaturized on photo-programmable
chips (Tian et al., 2004).
(2) Due to the inherently error-prone chemical DNA synthesis
process, sequence verification of the novel fragment is
important. As the error-frequency is increasing with oligo-
nucleotide length but oligo-assembly is simpler with longer
molecules, there should be an optimal oligonucleotide length
from which to start assembly. This length is estimated to
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be 40 bp. From there, intermediary 500 bp ‘synthons’ are
assembled, which in turn are assembled into 5 kb fragments
(Kodumal et al., 2004).
(3) Finally, different techniques canbe used to remove the remain-
ing errors: e.g. it is highly unlikely that two synthesized
complementary oligonucleotides will have mutations in
complementary positions, so there will be mismatches.
These can serve as entry points for digestion of different
enzyme systems (Greger and Kemper, 1998; Smith and
Modrich, 1997; Young and Dong, 2004). Alternatively,
erroneous oligonucleotides can be sorted out by having all
the oligonucleotides designed to hybridize at one specific tem-
perature and then very carefully control this temperature dur-
ing hybridization. Oligonucleotides withmismatches can then
be washed away (Tian et al., 2004). Combinations of these
approaches put the current accuracy at error rates of only 1 in
1400 bp (Tian et al., 2004).
In summary, if synthesis costs can be reduced by a factor ten
from the current prices in the order of US $1 per bp, it is clear
that DNA de novo synthesis will become an overwhelming force in
systems fabrication. Coupled to community-wide standards on the
availability, documentation, characterization and standardization of
parts, there is reasonable perspective to eliminate system fabrication
as a prohibitive part in future synthetic biology endeavors.
3.3 Providing engineering chassis
Designed and synthesized DNA segments that encode novel
functions need to be implemented into a suitable organism, for
the time being, by one of the many available genome engineering
techniques (cf. Kolisnychenko et al., 2002) or in the future by novel
mega-size cloning strategies (Itaya et al., 2005). As the complexity
of existing biological systems is the major problem in implementing
synthetic biology’s engineering vision, it is desirable to reduce this
complexity. One option is to reduce the genome of the host—the
chassis—into which the new sequence is implemented, which
would eliminate many possibilities for interference. For an intended
chemical production with the designed system, this genome reduc-
tion will probably be limited to reducing the metabolic capabilities
of a strain. A true ‘minimal genome’—the minimum set of
genes that is necessary for a cell to propagate under specific envi-
ronmental conditions—would be a useful point to start when trying
to engage in re-building more complex systems (Forster and
Church, 2006).
According to theoretical considerations, growth in the presence of
a rich but synthetic and defined medium requires as few as 206
genes, basically comprising the DNA replication, transcriptional
and translational machinery, rudimentary DNA repair functions,
protein processing and degradation, cell division and rudimentary
metabolic and energy functions (Gil et al., 2004). Towards this goal,
one can either substantially reduce the relatively large genomes of
established model systems and exploit the abundance of molecular
biology tools for these model organisms or work on the already very
small genome of other organisms in exchange for the requirement to
develop novel molecular biology tools.
Regarding the latter, non-pathogenic Mesoplasma florum with
very attractive cultivation properties and a genome size of 793
kb is currently being established as such a chassis. Its genomic
sequence has recently become available and molecular biology
methods are developed. A similar approach is followed with
Mycoplasma genitalium, for which extensive data on non-essential
genes is available (Glass et al., 2006).
Regarding the former, a prominent example is Escherichia coli
whose genome has been reduced in various projects by 6% (Yu
et al., 2002), 8% (Kolisnychenko et al., 2002) or 15% (Posfai et al.,
2006 ), without any noticeable effect on the investigated physiolo-
gical properties and by 30% resulting in defects in cell replication
(Hashimoto et al., 2005). Bacillus subtilis’ genome has been
reduced by 8%, again with only minor effects on physiology
(Westers et al., 2003), confirming the hypothesis that under con-
trolled laboratory conditions a substantial part of a bacterium’s
genome is indeed dispensable.
4 EXAMPLES FOR SYNTHETIC BIOLOGY
ENDEAVORS
The ultimate goal of synthetic biology is the efficient design of
biological systems. In a few areas, this has already advanced
quite substantially. Here, we will outline examples—at various
levels of complexity—of protein, circuit and system engineering.
4.1 Engineering of proteins
To facilitate the design process, it would be highly desirable to
have protein modules that are functionally self-contained and can
be freely combined to new functionalities. The domain architecture
of many regulatory proteins plays very much in favor of such
approaches.
One specific example of how novel functionality can be obtained
from recombining protein modules is the design of polydactyl
zinc finger DNA-binding proteins (Blancafort et al., 2004). Here,
combinations of zinc finger domains provide the sequence specifi-
city of the DNA–binding domain (DBD) by essentially recognizing
a subset of three or four nucleotides per zinc finger domain. Such
proteins display modularity in two ways: typically, the DBD is
functionally independent from the effector domain and zinc finger
domains are functionally relatively independent from each other.
Therefore by selecting a set of specific zinc fingers in silico one
can specify arbitrary sequence specificity for a novel DBD, which
can then be coupled to a novel effector domain.
The success rates in this process can be quite attractive. The zinc-
finger design can e.g. be based on a comprehensive table of zinc
fingers covering all possible binding DNA-sequences for a single
zinc-finger. This table has been compiled by extrapolations from
X-ray structures and 5 out of 10 combinations of 3 zinc-fingers
selected from this table showed indeed excellent DNA-binding
properties for decamer DNA-sequences (Sera and Uranga, 2002).
Even better rates can be achieved when the functional modularity
between adjacent zinc-fingers is improved by combinatorial and
rational approaches. Currently, the corresponding designs are avail-
able for all possible 50-GNN (Segal et al., 1999), 50-ANN (Dreier
et al., 2001) and 50-CNN (Dreier et al., 2005) DNA-target sequences
and have been successfully exploited for specific binding of up to
octadecamer DNA sequences (Dreier et al., 2001).
Similar functional reprogramming could also be achieved on
the level of protein–protein interactions with signaling proteins.
For example, the eukaryotic neuronal N-WASP protein accom-
modates the substitution of its receiving domains or changes in
their affinities, insertion of alternative linker structures between
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2793
domains, different N-WASP output domains and even different
domain architectures. These changes produced proteins with
completely new logical behavior (Dueber et al., 2003).
Other exploitations of functional modularity in signaling
pathways stem from scaffold proteins that recruit a kinase and
the kinase’s substrate, assemble them in close proximity for
phosphorylation and thus provide specificity (Park et al., 2003).
The domain structure of theses scaffolds allows to recombine
scaffolds that share the same ‘nodes’ (a common kinase that
interacts with both scaffolds) and thus to redirect signals to
novel outputs, such as making osmotolerance a function of the
induction of the mating signaling pathway (Park et al., 2003). In
human cell lines, mitogenic signals can be rewired to apoptotic
behavior by the same strategy (Howard et al., 2003).
The above results have to be seen in the light of recent
improvements in the algorithms for computational design of pro-
teins that allow e.g. the rational engineering of novel substrate
binding specificities (Looger et al., 2003) or even the conversion
of binding proteins into functional enzymes (Dwyer et al., 2004).
Taken together, the recent successes in modular protein engineering
and computational design suggest that rational protein design for
many applications will be feasible in the near future.
4.2 Engineering of artificial gene networks
Significant efforts were recently undertaken in the design of
artificial genetic networks in prokaryotic and eukaryotic systems.
Here, different genetic elements or ‘parts’ are (ultimately) rationally
combined to ‘devices’ to realize specific cellular behaviors that
have frequently analogies to elements from electric circuits such
as switches and oscillators. We will outline recent efforts in the
development of artificial gene networks.
4.2.1 Switches A switch lets the cell adopt one of two possible
states, depending either on the presence or absence of a chemical
inducer or on two separate external stimuli (toggle switch) (Becskei
et al., 2001).
The latter behavior can be easily designed from any two repres-
sors that reciprocally inhibit the transcription of their genes
(Fig. 2A) (Gardner et al., 2000; Kramer et al., 2004). Switching
between states can be achieved by intermittently inactivating the
repressor that maintains the current state (such as adding a chemical
inducer or increasing the temperature). Essentially, this property
conveys a cell with a memory of its previous cultivation history and
thus represents an epigenetic toggle switch.
The former behavior requires positive feedback in the regulatory
processes, such as (1) the positive autoregulation of a positive
regulator’s gene transcription or (2) the concomitant upregulation
of an operon by external inducer and of the gene that encodes the
transporter protein for entrance of the inducer. Besides the artificial
design of such systems, this behavior is rather common in a number
of well-characterized bacterial expression systems such as the
bacterial lactose and arabinose systems (Atkinson et al., 2003;
Khlebnikov et al., 2001; Ozbudak et al., 2004; Vilar et al., 2003).
In addition, the switches can be engineered with a hysteretic
character, so that the system switches into the ‘ON’ state at a higher
concentration of external signal than is required to switch back to
the ‘OFF’ state. This requires that the concentration of activator or
active repressor can be made a function of the history of the cell, e.g.
by adding another regulatory layer on top of the positive feedback
element. This can be a concentration-dependent inactivation of a
repressor that competes with an activator (Fig. 2B). Depending on
the previous state of the cell, a given concentration of active repres-
sor interacts with either high or low concentrations of activators,
leading to a differentiation in response depending on the history
(Atkinson et al., 2003; Kramer and Fussenegger, 2005).
4.2.2 Complex networks An oscillator produces regular fluctua-
tions in network elements such as reporter proteins. Oscillators have
been realized in two ways: as ring oscillators (‘repressilators’;
Fig. 2C) or as a combination of activation and repression elements.
The ring oscillator consists of three repressor genes that are coupled
to three corresponding promoters in such a way, that each repressor
protein can turn off the synthesis of one other repressor protein. This
design worked on single cell level, but not on culture-level, which
probably has to do with the noise involved on gene expression level
(see below; Elowitz and Leibler, 2000). However, by combining
positive and negative regulation, it is possible to reduce the noise to
such a degree that population-synchronized oscillation behavior
over three periods can be observed in a turbidostat (Atkinson
et al., 2003). Interestingly, such oscillating systems can be extended
to include metabolite concentrations (Fung et al., 2005).
In order to execute ever more complex logical behavior, it will be
important to be able to ‘integrate’ more and more signals into
determining one or more cellular functions. This is facilitated by
the high level of modularity in the regulatory elements of eukaryotic
systems. This modularity makes them particularly amenable to
design and can be used to implement a wide variety of logical
behaviors for two and three signal inputs while exploiting only a
limited number of genetic elements (Kramer et al., 2004).
4.2.3 Networks for intercellular communications Creating
macroscopically observable artificial functional behavior in a cell
population requires some kind of synchronization. Such synchron-
ization can be enforced by adding chemical inducers or by letting
the cells themselves produce a signal in response to a change in a
culture property. One example for such a property is cell density
which can be communicated by quorum sensing, for example via the
luxR/luxI system of Vibrio fischeri or via artificially engineered
systems (Bulter et al., 2004).
The luxR/luxI system has been used to trigger a variety of
population–density dependent responses, such as flipping of a
toggle switch (Kobayashi et al., 2004) or programmed population
control (You et al., 2004). The system has also been exploited to
design spatial patterns of behavior that re-build aspects of multi-
cellular systems (Fig. 2D): when producer cells send the auto-
inducer signal of the lux system via diffusion through a plate,
cells at different distances from the senders experience differently
steep gradients once the autoinducer reaches them. Alternatively,
cells can be used to detect the differences in inducer concentration
in resulting (quasi-)steady state. Networks can be designed which
are able to detect these rather subtle differences in environmental
conditions and which translate them into adequate cellular
responses such as different pulses of reporter proteins or
stable colorimetric patterns (Basu et al., 2005, 2004), introducing
space as an additional design parameter into the synthetic biology
realm.
4.2.4 Issues related to the design of genetic circuits For the
design of genetic networks, the availability of functional elements
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with specific properties (such as binding constants and degradation
rates) that fit the design purpose is crucial. So far, we are only at
the beginning of being able to easily measure, let alone program
kinetic parameters, co-operativities or binding constants (see
above). Consequently, the design process remains–for the time
being–an iterative process that still contains considerable elements
of trial and error. Nevertheless, some work-around tools are avail-
able today in order to, at least crudely, shift certain characteristics
from wild-type values to values that allow a desired behavior to
be implemented. These include variations in gene dosage via
changes in plasmid replicon (e.g. Atkinson et al., 2003), the increase
of protein degradation rates by fusion to suitable protease sensitive
tag-sequences (Elowitz and Leibler, 2000), variations in the strength
of RBSs (e.g. Yokobayashi et al., 2002) or drawing on the
large number of mutants that are available for a number of
model systems (such as phage l, the lac system or the tet system).
Alternatively, parameters can be adapted to the desired behavior by
directed evolution, if a suitable assay is available (Yokobayashi
et al., 2002). However, it is not really clear how such directed
evolution assays can be easily tailored to screen for relatively subtle
differences in properties important for optimized design. In sum-
mary, a primary task for the immediate future is to gain access to
complete system parameter sets, which can then serve as the starting
point to produce parts with parameter values that span suitable
ranges.
4.3 Engineering of systems
Synthetic biology is a very young discipline that follows a powerful
technological vision. However, there are no examples available
Fig. 2. Artificial genetic networks in E.coli and mammalian cells. Boxes represent genes, arrows promoters, boxes on arrows operators. Lines connecting
promoters and genes represent connectingDNA that is not further specified here. Different lines represent different replicons. Terminators and ribosome binding
sites have not been included. Ovals represent proteins. Lines ending in arrows symbolize activation, lines ending in orthogonal lines represent blocking.
Stars indicate proteins (and their corresponding genes) that carry a tag that targets them for accelerated degradation. (A) Toggle switch in E.coli. IPTG:
isopropylthiogalactoside, inactivates LacI; PL: Left promoter from phage l, CI-repressible; Ptrc-2: fusion promoter of promoters from tryptophane- and lac
operon, LacI-repressible; gfp: gene encoding green fluorescent protein. LacI: E.coli Lac-repressor. CIts: temperature sensitive variant of phage l CI repressor.
(B) Hysteretic network behavior in chinese hamster ovary cells: PSV40: simian virus 40 early promoter; PhCMVmin: truncated version of the human cytome-
galovirus promoter that can be made responsive to the tet-repressor; E.coli’s erythromycin-repressible repressor MphR(A); KRAB (Kruppel-associated box):
human transrepressor domain; SEAP: human placental secreted alkaline phosphatase, can be assayed by its color-inducing dephosphorylation activity for
p-nitrophenylphophate; TetR: here: DNA binding domain of the tet-repressor, interacting with tet-operator; VP16: transactivation domain of protein VP16 of
Herpes simplex virus; tetO7: seven copies of tet-operator; ETR8: eight MphR(A)-binding operators. (C) E.coli repressilator: PL::tetO1: fusion of the PL promoter
and the operator site two of the Tn10 tetracycline resistance operon, makes the PL promoter repressible by bacterial TetR; PL::lacO1: fusion of the PL promoter to
operator sequences of the lac operon, makes the promoter repressible by LacI; PR: right promoter from phage l, CI-repressible. (D) AHL:
acly-homoserinelactone, activates LuxR; PluxL: left promoter for autoregulated luxR expression; PluxR: right promoter for luxI expression. Requires
LuxR activated by AHL for expression; LuxR: regulator for activating transcription from PluxR; PluxR::ORI: fusion of PluxR and operator site from PR,
making the promoter repressible by CI; LuxI: enzyme catalyzing formation of AHL; PR::O12: truncated version of the l PR promoter that lacks the third
operator site. LacIM1: Protein identical to LacI but expressed from a codon-modified lacIM1 to prevent recombination with the second lacI. For further details
and references, see text.
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where the whole approach (as sketched above) has been imple-
mented. Still, in some cases specific aspects of synthetic biology
have been of critical importance. We will discuss the following
examples: the design of an E.coli capable of image processing,
refactoring of the phage T7, the design of novel polyketide anti-
biotics and the manufacturing of precursors for the anti-malaria
drug artemisinin.
An original example for new applications that derives from
the interface of engineering and life sciences, which came out
of the iGEM student competition, is the image-processing E.coli.
By designing proteins that couple light-detection to well-known
E.coli regulatory circuits, first steps towards light-detecting pixel
sizes of micrometer dimensions are possible (Levskaya et al., 2005).
A more fundamental aspect is covered by the work on the
phage T7, which tries to help to answer the question whether
it is indeed possible to refactor significant portions of small
genomes. In other words, can we indeed modify those genomes
according to the requirements of ‘engineerability’ such as mono-
functionality of a part of the sequence and organization of the
DNA into functional segments. Refactoring 10 kb of the T7
genome, representing about a quarter of the total genome, still
produces functional phages, though their efficiency in propagation
is reduced (Chan et al., 2005). This is an important validation
of the synthetic biology approach, even though on a small scale.
It remains to be seen whether the same concepts can be applied to
more complex systems such as microbes.
Two examples for application of synthetic biology concepts come
from the area of pharmaceutical production and involve primarily
the opportunities offered by de novo DNA synthesis, such as the
direct adaptation of codon usage, implementation of suitable regu-
latory circuitry and the possibility to modularize the DNA
sequences by restriction sites to facilitate iterative optimizations.
The first example involves the adaptation of polyketide synthesis to
well studied E.coli production strains (Kodumal et al., 2004) and the
subsequent design of novel polyketides by semi-randomized
recombination of polyketide synthase genes. These recombinations
were easily enforced along the interfaces of the different functional
modules that make up a synthase and resulted in a rather high
success rate of detecting novel polyketides (Menzella et al., 2005).
Along similar lines, another project that very much catches the
spirit of synthetic biology is the construction, from scratch, of a
cheap terpenoid production pathway in E.coli leading to artemisinic
acid, a precursor to the anti-malaria drug artemisinin. This goal
essentially requires the design of an entirely new pathway in a
suitable production organism. The corresponding pathway elements
can be recruited from bacteria (E.coli), yeast (Saccharomyces cere-
visiae) and plant (Artemisa annua), redesigned and functionally
expressed in bacteria or yeast, effectively paving the road to a
low-cost production route to effective malaria treatment (Martin
et al., 2003; Ro et al., 2006).
Although the design of novel biological systems is only begin-
ning, all ingredients of the engineering approach are visible: the role
of de novo DNA synthesis, the design of well-behaved parts on the
DNA and protein level, the organization of parts into the next
functional level of devices and the corresponding abstractions
and the attempt to introduce standardization, even though for the
time being only on a parts level. With the design of ever more
complex systems, the need to emphasize these elements will
undoubtedly increase.
5 REQUIREMENTS FOR COMPUTATIONAL
AND INFORMATIC EXPERTISE
Synthetic biology encompasses the building of novel biological
entities for useful purposes and the corresponding endeavors can
be subdivided into two distinct types of tasks: systems design and
systems fabrication. Here, we will discuss the essential elements of
these two tasks with a special focus on the computational and
informatics requirements.
Fabrication deals with the transformation of design plans
into actual physical instances. Today, this still involves a signi-
ficant amount of cloning work, which should decrease in the future
due to de novo DNA synthesis (see above). The fabrication as
such, is not expected to create a great demand for novel informatics
tools.
In contrast, systems design consisting of forward-engineering of
biological parts, devices or systems strongly relies on computing
and informatics tools that assist the design process. Ultimately, it
would be desirable to have computer aided design tools—CAD
tools for biological engineering—in analogy to the respective soft-
ware tools in the areas of mechanical or civil engineering. Using
such software, the synthetic biology design engineer would try to
improve the behavior of a biological system in silico by optimizing
design parameters targeting a selected objective function. Design
variants would be tested computationally by means of simulations.
Such design tools will be based on quantitative mechanistic mod-
els that reproduce biological behavior and–in order to be useful for
forward-engineering design—would also have predictive power. In
biology, we have not yet reached a level of understanding where
such models can be developed on a large scale and consequently,
true biological engineering is hardly possible until now (Endy and
Brent, 2001). In fact, in most cases today, we are faced with highly
uncertain or even unknown model topologies, mechanisms and
parameters. The recent advances in the post-genomic research
and especially in systems biology, however, provide hope that
sooner or later we will be able to draw on a body of knowledge
that allows for the envisioned directed engineering of biology (Endy
and Brent, 2001). Ultimately, mathematical models developed for
research purposes (e.g. in systems biology) will be employed as
design models in synthetic biology. In contrast to the current lack of
predictive models, tools for modeling and simulation exist in large
numbers (cf. Lemerle et al., 2005).
We envision that in the long run we will require models and
design software for the following tasks: (1) sequence–based (ab
initio) prediction of structure, function and interactions of macro-
molecules, in particular proteins and mRNA, (2) prediction of the
dynamics of signaling and regulatory networks; and (3) prediction
of the dynamics of metabolic networks. For each of these areas,
we will shortly sketch the current status of development and also
elaborate on future tasks.
5.1 Design of functions and interactions of
macromolecules
We would like to predict—starting from a linear sequence of
nucleotides or amino acids—2D (mRNA) and 3D structures of
the respective macromolecules (RNA, proteins), as well as their
function and their interaction parameters with other cellular com-
ponents (DNA, metabolites, etc.). In other words, as outlined above
we would like to have the possibility to modify sequences in a
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targeted manner to obtain, e.g. novel transcription factors
(i.e. with altered binding constants or kinetics) or proteins with
novel functions.
However today, as an example de novo protein structure predic-
tion from a linear amino acids sequence can only be achieved for
small protein domains at significant computational costs (Bradley
et al., 2005; Misura et al., 2006). Nevertheless, starting from known
structures of ‘scaffold’ proteins, design methods are available,
which can be used to rationally modify the proteins’ structure
and function, i.e. to build completely new active sites into proteins
(Dwyer et al., 2004) or to redesign binding specificities of proteins
(Looger et al., 2003). However, such design processes still go
through several cycles of iterative improvement involving design,
analysis, redesign, etc. where computational tools such as FoldX
(Schymkowitz et al., 2005) are typically employed. In other
words, the design of tailored catalytic activities on artificial
proteins seems to be within reach, while quantitative prediction
of enzymatic activity and selectivity from 3D protein structures
in general is not yet feasible. For further information on the current
status in modeling of protein structures and interactions, the reader
is referred to a recent review (Schueler-Furman et al., 2005).
Based on structure models, molecular dynamics simulation
have shown to be a versatile tool to investigate the dynamic beha-
vior of complexes between DNA binding sites and respective DNA
target sites (Marco et al., 2003; Obika et al., 2003). These tools
can also be employed to predict the effect of structural modulations
on protein–ligand interactions in a way that would allow forward-
engineering design of, e.g. DNA-binding specificity of transcription
factors.
5.2 Design of signaling and regulatory networks
Artificial signaling and regulatory gene networks will need to
be assembled for synthetic biology. Today, such circuits are still
frequently assembled by intuition and optimized through several
rounds of trial and error (Kærn et al., 2003) and the mathematical
models are only developed once proper in vivo function has been
demonstrated. Deterministic or stochastic models (or a combination
of both) are then used to describe the observed dynamic behavior
of the circuit (Fung et al., 2005; Gardner et al., 2000; Kobayashi
et al., 2004; You et al., 2004).
Ideal, however, would be models that allow deriving in silico
suggestions for optimal design strategies or debugging, prior to
implementation of the circuit in vivo (Gardner et al., 2000;
Sprinzak and Elowitz, 2005). Such models should be able to capture
the dynamic behavior of the gene networks. In cases where only
small molecule numbers are involved (as in gene transcription or
translation, where transcription factors and mRNA molecules only
occur in low copy numbers), the models would also need to be able
to reproduce the inherent stochasticity of such processes. This is
imperative as it was shown that stochasticity in combination with
certain system architectures can result in different system states
(Kærn et al., 2005; Pedraza and van Oudenaarden, 2005). A robust
design of new devices and systems must exclude such eventualities.
In summary, to enable the envisioned forward-engineering
(model-based) design of signaling and regulatory circuits, improve-
ments are required in the following areas: It is necessary (1) to
obtain an improved quantitative understanding of regulatory and
signaling processes (Sprinzak and Elowitz, 2005); (2) to develop
effective rules (cf. Wall et al., 2003, 2004) and standards for
characterizing modules (Kærn et al., 2003; Sprinzak and
Elowitz, 2005) and (3) to improve multiscale simulation algorithms
as the existing ones are limited in a way that the participating
reactions have to occur on a comparative time scale and the parti-
cipating reaction species have to fulfill certain population size
requirements.
5.3 Design of metabolic networks
Besides the design and construction of signaling and regulatory
networks, we would also like to engineer metabolic networks.
Models currently available in this area are (1) stoichiometric models
which display—in most cases on a genome-wide level—an
organism’s metabolic (stoichiometric) capabilities and (2) enzym-
atic reaction network models, which describe the kinetics of a
metabolic network but mostly cover only small and well studied
areas of metabolism.
For design of metabolic networks based on stoichiometric
models, the most prominent tools to analyze these networks are
flux balance analysis (FBA) (Edwards et al., 1999; Varma and
Palsson, 1994) and elementary flux mode (Schuster et al., 1999)
or extreme pathways analysis (Schilling et al., 2000). Extended
tools–conceptually based on FBA–were developed that allow
assisting the targeted modification of existing or the design of
new, metabolic networks (Patil et al., 2005; Pharkya et al., 2004).
On the side of the kinetic models (consisting of ordinary differ-
ential equations), a large set of models is available from model
repositories (cf. www.siliconcell.net). However, due to largely
unknown reaction mechanisms and parameters, these models in
most cases only cover small parts of metabolism. Tools for mod-
eling and simulation are widely available ranging from general
simulation platforms, such as SmartCell (http://smartcell.embl.de/;
Ander et al., 2004), via object-oriented software suites (http://www.
e-cell.org) to web-based suites for modeling, simulation and anal-
ysis of biological cells (http://www.webcell.org/; Lee et al., 2006).
An overview about available tools can be obtained from http://sbml.
org.
6 CONCLUSION
The move from describing biology to exploiting it for our require-
ments has always been a part of the biological enterprise—and thus
always reflected the current main lines of biological research. So, as
molecular biology has for a long time attempted to unravel the
molecular mechanisms that are important in cellular function,
biotechnology has exploited this knowledge and adopted some of
these mechanisms to produce chemicals, enzymes and biopharma-
ceuticals. Now, synthetic biology is adopting a very ambitious
agenda in building novel biological entities on an ever more com-
plex level for novel applications.
Currently, biology is characterized by the shift from the study of
single aspects of systems to the appreciation of the system as a
whole. With this goes the expectation that many of the failures that
biotechnology suffered can be understood from this new perspec-
tive. At the same time, to advance exploitation of biological systems
(instead of single aspects), we adopt an approach that is sufficiently
organized and robust. We adapt our technologies—e.g. in
fabrication—and methodologies—such as design—to the new
system-scale of the task through adopting the crucial elements
of classical, non-life science related engineering disciplines.
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The aspects that have been discussed here, from de novo DNA
synthesis via modular protein design, the design of novel gene
networks, to the reconstruction of artificial pathways, address–in
our view–this transition in an exemplary way.
Conflict of Interest: none declared.
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